Bayer Schering Pharma
, the pharmaceutical division of
Bayer HealthCarespecialising in women’s healthcare, cardiology, oncology and diagnostic imaging, is to establish a global research-and-development (R&D) centre in
.
The company will invest €100m (£90m) over the next five years to establish the facility in
‘Constantly improving the quality and output of research is crucial for a pharmaceutical company to bring novel therapies to patients,’ said Andreas Busch, member of the Board of Management of Bayer Schering Pharma and head of Global Drug Discovery. ‘We believe that
‘In addition to the establishment of development functions, we will also launch the Global Drug Discovery Innovation Centre here in
Poll: Should the UK’s railways be renationalised?
I think that a network inclusive of the vehicles on it would make sense. However it remains to be seen if there is any plan for it to be for the...